Downgrade SOLS to NEUTRAL (from BUY) with Shares Trading Roughly In-Line with our FVE of $65 per share
For context, Solstice Advanced Materials Inc. (NASDAQ: SOLS) completed its tax-free separation from Honeywell International Inc. (NYSE: HON) on October 29, 2025; following our initial NEUTRAL recommendation shares declined ~13.5% (underperforming the S&P and Russell by 9.65% and 7.75%, respectively), amid both technical index-related & natural shareholder rotation factors, prompting our upgrade to BUY on 11/19/2025 (see Update), since which time SOLS shares have sharply rebounded ~53% (outperforming the S&P and Russell by ~49% and 41%%, respectively).
In our view, besides being oversold in the low-$40’s amid the lack of an initial shareholder constituency within the larger parent (i.e., a greater Aerospace & Automation focus) the stock has re-rated away from a valuation that was more aligned with lower-margin/commoditized & highly levered peers, such as Chemours (NYSE: CC), toward higher-valued peers, such as Entegris (NASDAQ: ETNG) and Element Solutions (NYSE: ESI). Additionally, we perceive that shares have also benefited, as of late, from investor enthusiasm regarding the company’s defense (i.e., Spectra) and nuclear capabilities (i.e., SOLS is the sole domestic provider of uranium hexafluoride conversion services), which add additional levers to the company’s core refrigerant-centric growth/margin theme (i.e., data centers) and were, in our view, seemingly overlooked by existing/potential shareholders preceding SOLS’s debut.
That said, with shares currently trading in-line with our $65 fair value estimate (FVE) we think it reasonable/prudent to temper our previous bullish stance and lower our investment recommendation to NEUTRAL (from BUY).
In terms of guidance, recall management re-iterated its initial 2025E guidance on its most recent earnings conference call (see Exhibit 1), and its “Medium-Term” targets continue to call for low-to-mid single digit top-line growth, a mid-single digit adjusted EBITDA CAGR, and a free cash flow conversion ratio of greater than 70% (see Exhibit 2). Capital expenditures are projected to be in the mid-single digits (down from ~10% in 2025E), as a percentage of sales, and the net leverage target is ~1.5x (roughly in line with current levels).
The company intends to report 4Q 2025 and full-year results before the market open of February 11, 2026 and hold a conference call to discuss the results that morning at 8:30 a.m. (ET).
In terms of valuation, our fair value estimate of $65 per share, reflects a blended multiple of ~12x on 2026E EV/EBITDA as well as projected net debt of ~$1.7 billion and a diluted share count of ~160 million (see Exhibit 3 and Exhibit 4 on pages 2 and 3).
Please see the Spin-Off Report dated October 14, 2025, and the Updates from 10/16/2025, 10/30/2025 and 11/19/2026 as well as the Reference section on pages 4-8, for more information.